Ignite Creation Date:
2024-05-05 @ 5:12 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00406900
Status:
UNKNOWN
Last Update Posted:
2006-12-06
First Post:
2006-11-29
Brief Title:
Melanoma Inhibitory Activity MIA A Serological Marker for Metastatic Uveal Melanoma
Sponsor:
Ludwig-Maximilians - University of Munich
Organization:
Ludwig-Maximilians - University of Munich
Study Overview
Official Title:
None
Status:
UNKNOWN
Status Verified Date:
2006-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Uveal Melanoma is the most common primary intraocular tumor in adults Most tumors metastasize to the liver So far no sensitive or specific serological tumor marker is routinely used The marker Melanoma inhibitory activity is a promising marker Study hypothesis is to detect metastatic lesions in an early stage This would increase life expectance of our patients
Detailed Description:
Serum is taken from each melanoma patient at every follow up after signed concent With ELISA the marker MIA is evaluated An increase of MIA serum level will lead to search for metastasis by oncologists
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None